Enanta Pharmaceuticals (FRA:9EP) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9EP Enanta Pharmaceuticals Inc FRA:9EP
55 GF Score
Price €10.60
GF Value €6.67
! 6 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Enanta Pharmaceuticals  (FRA:9EP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Enanta Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Enanta Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.49 3.26 0.61 0.53 0.61

Enanta Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.59 0.82 0.66 0.77

FRA:9EP vs LXEO, XFOR, GALT: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:9EP
55GF Score
Enanta Pharmaceuticals Inc FRA:9EP
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Enanta Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Enanta Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.036/333.9520*333.9520
=3.036

Current CPI (Jun. 2026) = 333.9520.

Enanta Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 12.618 241.428 17.454
201612 13.353 241.432 18.470
201703 13.053 243.801 17.880
201706 11.981 244.955 16.334
201709 13.346 246.819 18.057
201712 13.811 246.524 18.709
201803 14.075 249.554 18.835
201806 15.966 251.989 21.159
201809 17.476 252.439 23.119
201812 19.212 251.233 25.538
201903 19.751 254.202 25.947
201906 19.992 256.143 26.065
201909 21.531 256.759 28.004
201912 21.689 256.974 28.186
202003 22.161 258.115 28.672
202006 21.319 257.797 27.617
202009 19.351 260.280 24.828
202012 18.340 260.474 23.514
202103 18.380 264.877 23.173
202106 17.433 271.696 21.428
202109 17.030 274.310 20.733
202112 16.483 278.802 19.744
202203 15.631 287.504 18.156
202206 15.605 296.311 17.587
202209 15.776 296.808 17.750
202212 13.497 296.797 15.187
202303 11.779 301.836 13.032
202306 10.353 305.109 11.332
202309 9.721 307.789 10.547
202312 8.211 306.746 8.939
202403 7.262 312.332 7.765
202406 6.560 314.175 6.973
202409 5.446 315.301 5.768
202412 5.062 315.605 5.356
202503 4.051 319.799 4.230
202506 3.159 322.561 3.271
202509 2.575 324.800 2.648
202512 3.714 324.054 3.827
202603 3.482 330.213 3.521
202606 3.036 333.952 3.036

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Enanta Pharmaceuticals (FRA:9EP) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of €10.60 is trading 58.9% above its estimated GF Value™ of €6.67.

Key valuation signals for FRA:9EP:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €6.67 vs. price of €10.60 (58.9% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the FRA:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enanta Pharmaceuticals Business Description

Other Exchanges ENTA:USA
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
55GF Score

Get the complete analysis for FRA:9EP

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.60
Price
€6.67
GF Value